Our preliminary experiment showed that SiHa cervical cancer cells, which have a higher RRM2 protein content, exhibit higher cell viability than Caski cervical cancer cells, which have a lower RRM2 protein content, based on MTT [3-(4,5-cimethylthiazol-2-yl)- 2,5-diphenyl tetrazolium bromide] assay after the treatment of cisplatin. The gene discussed is RRM2; the disease is cervical cancer.